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In this issue, Dang et al. (2011) report a role for the hypoxia-induced transcription factor HIF-1a in
regulating the differentiation of T cell subsets that impact both inflammation and its resolution. Their
findings illustrate howmetabolic signals can alter the balance between inflammation and tolerance
and present a potential therapeutic opportunity for the treatment of diseases associated with
chronic inflammation.For two decades, a central paradigm has
been that pathogen-stimulated innate im-
mune cells produce cytokines to educate
the adaptive T helper (Th) response in
order to appropriately deal with foreign
antigens. For example, the Th17 subset,
defined by the expression of the pro-
inflammatory cytokine IL-17A and tran-
scription factor RORgt, is generated in
response to gut infections such as
Citrobacter rodentium (Mangan et al.,
2006), as well as normal gut constituents
such as segmented filamentous bac-
teria (Ivanov et al., 2009). By contrast,
peripheral generation of induced regula-
tory T cells (iTreg) suppresses immune
responses and facilitates tolerance to
commensal microbiota (Round and Maz-
manian, 2010). The mechanism under-
lying the selection of these T cell sub-
sets of opposing function centers on the
level of induction of interleukin 6 (IL-6) in
the microenvironment. In conjunction with
TGFb, high levels of IL-6 facilitate Th17
development, whereas low levels result in
iTreg generation (Bettelli et al., 2006; Man-
gan et al., 2006). Though the role of cyto-
kines in the microenvironment is well
appreciated in the differentiation of both
Th17 cells and iTregs, how other cues
are sensed and interpreted is an area of
much interest. In this issue, Dang and
colleagues (Dang et al., 2011) reveal a
mechanism by which an environmental
cue, hypoxia, facilitates differentiation
toward the proinflammatory Th17 pheno-
type while simultaneously inhibiting differ-
entiation toward tolerogenic iTregs. The
mechanism centers on the T cell intrinsic
upregulation of the transcription factorhypoxia-inducible factor 1a (HIF-1a), a
key sensor of hypoxia that mediates the
metabolic switch from oxidative phos-
phorylation to anaerobic glycolysis.
A potential role for HIF-1a in Th17
biology was initially suggested by studies
in tumor cells showing that HIF-1a ex-
pression is dependent on Stat3, a key
transcription factor for Th17 differentia-
tion. Dang et al. first show that HIF-1a is
expressed in T cells upon T cell receptor
(TCR) stimulation and that its expression
is further induced during hypoxia as well
as downstream of IL-6- and Stat3-depen-
dent Th17 differentiation. Importantly,
HIF-1a appears to be both necessary
and sufficient for Th17 development, as
overexpression could induce Th17 cells
without the proper cytokine milieu, and
HIF-1a deficiency specifically blocked
Th17 development, but not Th1 or Th2
development. The mechanism by which
HIF-1a controls Th17 expression is cen-
tered on RORgt, a transcription factor
that is critical to Th17 differentiation.
HIF-1a binds to the promoter of the
RORgt gene and induces its transcrip-
tional upregulation. In addition, HIF-1a
forms a complex with RORgt and p300,
which binds to the promoter of IL-17A,
the signature Th17 cytokine, and triggers
its expression.
Strikingly, Dang et al. also reveal a role
for HIF-1a as a negative regulator of iTreg
differentiation. T cells that are deficient in
HIF-1a exhibited increased expression of
the transcription factor Foxp3, which is
essential for Treg development and func-
tion. HIF-1a appears to utilize a direct
mechanism of action, binding to Foxp3Cell 146, Sand targeting it for ubiquitin-mediated
proteolysis. Because Foxp3 may operate
in a feed-forward loop to stabilize its own
expression (Gavin et al., 2007) and inhibit
RORgt (Yang et al., 2008), a decrease in
Foxp3 protein levels can result in failure
to become bona fide iTregs. In the differ-
entiation of these Th subsets with oppos-
ing functions, the expression of HIF-1a
may tip the balance point via its concomi-
tant and opposite actions on transcription
factors that are essential for the develop-
ment of each subset. Thus, selection of
Th17 versus iTreg cells may be closer to
a digital, rather than analog, interpretation
of HIF-1a levels. Once a critical level of
HIF-1a and RORgt expression is reached,
the cell becomes Th17, contributing to an
inflammatory environment, which would
increase hypoxia and further serve to up-
regulate HIF-1a.
Dang et al. show that hypoxia facilitates
Th17 generation in vitro and further ob-
serve that the absence of HIF-1a impairs
the generation of Th17 cells in vivo, result-
ing in resistance to experimental autoim-
mune encephalomyelitis (EAE). The ab-
sence of HIF-1a also results in increased
frequency of Tregs in the gut. It is inter-
esting to note that the gut, which is
considered to be relatively hypoxic, is
also the site where most Th17 cells are
found in normal mice. A hypoxic environ-
ment in itself does not appear to be suffi-
cient, as Th17 cells are greatly reduced in
the absence of specific strains of com-
mensal gut bacteria (Ivanov et al., 2009).
Whether bacterial strains associated
with Th17 development affect the oxygen
tension in the gut is unknown. Indeed, theeptember 2, 2011 ª2011 Elsevier Inc. 673
Figure 1. ProposedModel for HIF-1a in Th17
and iTreg Cell Differentiation
T cell receptor (TCR) signaling, hypoxia via mTOR,
and IL-6 via Stat3 all contribute to the induction of
HIF-1a, a transcription factor that induces
expression of RORgt, a key regulator of Th17
differentiation. HIF-1a further supports Th17
function by binding in a complex with RORgt and
p300 to allow expression of the canonical Th17
cytokine IL-17A. Moreover, HIF-1a also promotes
degradation of the transcription Foxp3, a key
transcription factor that promotes the Treg lineage
via a proposed ubiquitination pathway. In this way,
the level of HIF-1a might induce, in a ‘‘digital’’
fashion, a molecular switch from iTreg to Th17
differentiation. Because the local environment of
the gut and that of sites of inflammation are asso-
ciated with hypoxia, these conditions would be
hypothesized to promote the development of
proinflammatory Th17 cells. Th17 cells via the
production of IL-17A would further enhance the
inflammatory process resulting in increased
hypoxia, thereby acting as a feed-forward loop. If
the source of antigenic stimulation (either from
pathogenic or commensal organisms) cannot be
eliminated by the Th17 response, this could result
in chronic inflammatory conditions such as
inflammatory bowel disease.question of howmicrobiota affects the gut
microenvironment and how that, in turn,
affects immune cells residing there is
only beginning to be explored. HIF-1a is
expressed in T cells under nonhypoxic
conditions, complicating the interpreta-
tion of results using HIF-1a deficient cells674 Cell 146, September 2, 2011 ª2011 Elseto address the role of hypoxia in physio-
logical settings. Thus, the increased fre-
quency of Tregs in the gut of HIF-1a-
deficient mice may be related to the basal
role of HIF-1a in Th17 versus iTreg devel-
opment rather than the inability to upregu-
late HIF-1a in response to hypoxia and the
ensuing increase in Th17 cytokine
production. Because HIF-1a expression
can be upregulated by both cytokines
and hypoxia, further studies will be neces-
sary to examine the relative contributions
of each to the differentiation of Th17 and
iTreg cells.
Roles for metabolic signaling path-
ways in Th cell differentiation have been
suggested by other studies. A study of
mTOR complexes, known metabolic sen-
sors, revealed distinct roles of mTORC1
and -2 in Th1/Th17andTh2differentiation,
respectively (Delgoffe et al., 2011). Similar
to Dang et al., another study of HIF-1a
suggested that it is involved in Th17 and
iTreg differentiation but ascribed the role
of HIF-1a to upregulation of glycolysis
(Shi et al., 2011) and not as a direct effect
of HIF-1a on RORgt and Foxp3. Further
studies will be required to reconcile these
differences. Nevertheless, it is clear that
environmental signals should be included
in the paradigm of Th differentiation.
The findings by Dang et al. lead to a
model in which hypoxia, resulting from
inflammation or from a predisposed local
microenvironment, plays a pivotal role
in the Th17/iTreg decision. Interestingly,
this model represents a positive feedback
loop in which HIF-1a induction leads to
Th17 differentiation which, in turn, causes
more inflammation, leading to greater
hypoxia and HIF-1a (Figure 1). In order
to re-establish immune homeostasis, the
antigenic insult inciting the inflammation
would need to be destroyed. In the case
of immune responses to commensal
bacteria in the gut, the large reservoir of
bacteria in the lumen of the colon may
make it impossible to completely elimi-
nate the source of antigen. This would
then lead to chronic inflammation and
inflammatory bowel disease (IBD). Inter-
estingly, human IBD is associated with in-
creasedTh17 responsesaswell asgeneticvier Inc.polymorphisms of genes related to Th17
biology (Abraham and Cho, 2009). Target-
ing HIF-1a via diminishing local hypoxia
or inhibition using pharmacologic agents
may therefore be useful in the treatment
of IBD.Though it remains tobeestablished
whether HIF-1a modulation can alter the
function of established Th17 cells, ROR
ligands have recently been reported to
inhibit IL-17 production in differentiated
Th17 cells (Solt et al., 2011). One potential
advantage of HIF-1a inhibitors compared
with ROR ligands is that it would be
predicted to block Th17 development
and concomitantly favor the generation
of tolerogenic Treg cells: a double-
pronged attack against immune-mediated
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